TY - JOUR
T1 - Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
AU - Mohamed, M. K.
AU - Ramalingam, S.
AU - Lin, Y.
AU - Gooding, W.
AU - Belani, C. P.
PY - 2005/5
Y1 - 2005/5
N2 - Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.
AB - Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n = 199) with advanced NSCLC were treated with gefitinib (250mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P<0.0001, log rank test). Patients with PS 0, 1 and 2 had MS of 8.4, 6.2 and 2.8 months, respectively (P <0.0002). The other factors did not impact survival. Conclusions: Occurence of skin rash and baseline PS of 0/1 were associated with improved survival with gefitinib for recurrent NSCLC patients at our institution.
UR - http://www.scopus.com/inward/record.url?scp=20044370274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20044370274&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdi157
DO - 10.1093/annonc/mdi157
M3 - Article
C2 - 15728108
AN - SCOPUS:20044370274
SN - 0923-7534
VL - 16
SP - 780
EP - 785
JO - Annals of Oncology
JF - Annals of Oncology
IS - 5
ER -